- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Governments Need Legal Solution as Telemedicine is Here to Stay, says GlobalData
GlobalData releases report on the physician's perspective of telemedicine.
With over three-quarters of US and European healthcare professionals saying they will continue using telemedicine after the COVID-19 crisis ends, governments are under pressure to make telemedicine a standard mode of care. Countries will need to establish consistent and clear legal frameworks for this technology in order to make permanent the temporary changes implemented to support telemedicine during the pandemic, says GlobalData.
GlobalData’s latest report, “Coronavirus Disease 2019 (COVID-19) Case Study: Telemedicine – Physician Perspective”, reveals that 72% of EU physicians were already using telemedicine to assess and treat their patients pre-COVID-19, while the adoption of telemedicine was lagging behind in US with 47% physicians using the technology.
A total of 267 specialists from the US, UK, France, Italy, Spain, Germany and Japan, including gastroenterologists, cardiologists, and pulmonologists, participated in online surveys that were fielded from May 27, 2020 to July 2, 2020.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
